Family Office

Updated:

resTORbio

Keziah Wheeler runs resTORbio as a beauty-product review affiliate site from Boston, not a biotech, earning Amazon commissions on ingredient comparisons.

resTORbio

resTORbio borrows the name of a shuttered biotech, but operates as a content publisher reviewing consumer beauty products. Its site publishes head-to-head shampoo and skincare comparisons — Ion vs. Malibu, Sunday Riley vs. Drunk Elephant — monetized entirely through the Amazon Associates affiliate program. There is no disclosed investment vehicle, portfolio of operating companies, or wealth-management mandate. Keziah Wheeler, who also founded the sulfate-free personal-care brand Videri Skincare, runs the site with her brother Austin. The editorial approach leans on ingredient scrutiny and positions product comparisons as biological research, though no clinical trials occur. Content addresses consumer-grade questions such as how to remove shampoo buildup or whether makeup expires. The firm lists a clinical trials email address, but no trials are active or registered. resTORbio operates from a single address at 500 Boylston Street in Boston, without disclosed additional offices or headcount. There is no public record of institutional capital, LP relationships, or investment-track metrics. The site's contact page references careers and investor relations email aliases, but both appear vestigial. Structurally, resTORbio is a single-revenue-source digital publisher with a domain that implies drug development. This gap between the domain's signaling and the actual affiliate-content model is its defining tension. There is no known succession plan, co-investment structure, or institutional-grade governance layer.

General information

Firm type

Family Office

Year founded

AUM

Undisclosed

Location

Region

North America

Country

United States

City

Boston

Corporate office

500 Boylston Street, 13th Floor, Boston, MA 02116

Principals

Keziah Wheeler

Founder

Austin Wheeler

Co-founder

Sector focus

Beauty & Personal CareMedia & Content

Frequently asked questions

Is resTORbio a biotech company or a content publisher?

resTORbio is a content publisher that runs an affiliate marketing website reviewing beauty and personal-care products. It shares its name with a former clinical-stage biopharmaceutical company (NASDAQ: TORC), which merged with Adicet Bio in 2020 and ceased to exist independently, but has no connection to that entity. The site generates revenue through the Amazon Associates program.

How does resTORbio make money?

The firm earns affiliate commissions when readers click product links and make purchases on Amazon. resTORbio discloses its participation in the Amazon Services LLC Associates Program on its website. No other revenue streams, such as investments, advisory fees, or direct product sales, are disclosed.

Does resTORbio run clinical trials?

The site's contact page lists a 'Clinical Trials' email address, but there is no evidence resTORbio conducts, sponsors, or monitors any clinical trials. The original resTORbio biotech investigated TORC1 pathway inhibitors for aging-related diseases, but that entity no longer operates.

Who runs investment decisions at resTORbio?

There is no investment activity. The site is a digital publisher, not an investment firm. Keziah Wheeler is listed as the founder and operator, while her brother Austin Wheeler is named as a co-founder.

What is resTORbio's relationship to Videri Skincare?

Keziah Wheeler, the founder of resTORbio, also founded Videri Skincare, a direct-to-consumer brand selling sulfate-free body wash and shampoo. Videri products are promoted on the resTORbio website, but each appears as a separate business.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on family offices?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo